Private Wealth Asset Management LLC boosted its position in Medtronic PLC (NYSE:MDT – Free Report) by 1,220.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 59,651 shares of the medical technology company’s stock after acquiring an additional 55,135 shares during the quarter. Private Wealth Asset Management LLC’s holdings in Medtronic were worth $5,147,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in MDT. Activest Wealth Management lifted its stake in Medtronic by 470.9% during the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 259 shares during the last quarter. IAG Wealth Partners LLC bought a new position in shares of Medtronic during the 2nd quarter valued at about $30,000. Team Financial Group LLC bought a new position in shares of Medtronic during the 3rd quarter valued at about $31,000. Avion Wealth raised its holdings in shares of Medtronic by 97.8% during the 3rd quarter. Avion Wealth now owns 362 shares of the medical technology company’s stock valued at $31,000 after buying an additional 179 shares in the last quarter. Finally, Pin Oak Investment Advisors Inc. purchased a new position in shares of Medtronic during the 2nd quarter valued at about $32,000. Institutional investors own 82.06% of the company’s stock.
Insider Transactions at Medtronic
In other news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president directly owned 42,186 shares in the company, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the sale, the chief executive officer directly owned 277,866 shares in the company, valued at $26,397,270. This trade represents a 15.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 61,903 shares of company stock valued at $5,889,203. Corporate insiders own 0.27% of the company’s stock.
Latest Medtronic News
Investors following MDT have been watching these news items:
- Positive Sentiment: BTIG Research raised its price target on Medtronic to $109 from $99 and reiterated a Buy rating, signaling confidence in further upside. BTIG Research rating and price target
- Positive Sentiment: Analyst coverage points to growth potential from adoption of Medtronic’s Hugo surgical robot, international expansion and Neuroscience products. A separate report projects strong growth in connected health devices through 2032, a market that includes Medtronic. Medtronic growth prospects Connected health devices market report
- Neutral Sentiment: A preview of Medtronic’s fiscal second-quarter results focused on expected metrics but did not report actual results, leaving investors awaiting the earnings update. Medtronic Q2 earnings preview
Medtronic Stock Down 0.1%
Shares of Medtronic stock opened at $100.57 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The stock has a market capitalization of $128.64 billion, a price-to-earnings ratio of 24.77, a P/E/G ratio of 2.36 and a beta of 0.56. The company’s 50 day moving average price is $94.44 and its 200-day moving average price is $88.47.
Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same quarter in the prior year, the company posted $1.26 EPS. Medtronic’s quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts forecast that Medtronic PLC will post 5.98 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on MDT. Stifel Nicolaus boosted their target price on Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research report on Wednesday, September 2nd. BTIG Research increased their price target on shares of Medtronic from $99.00 to $109.00 and gave the company a “buy” rating in a research report on Thursday. Royal Bank Of Canada reissued an “outperform” rating and set a $118.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. Needham & Company LLC restated a “buy” rating on shares of Medtronic in a report on Thursday, September 17th. Finally, Deutsche Bank reaffirmed a “hold” rating and issued a $92.00 price objective on shares of Medtronic in a research note on Thursday, September 3rd. Eighteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.17.
About Medtronic
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Featured Articles
- Five stocks we like better than Medtronic
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
